IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events
Rhea-AI Summary
IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, has announced its participation in two major investor relations events in May 2025:
- Barclays Hosted Event on May 8th, 2025 at 11:00 AM ET - featuring a fireside chat with President and CEO Yujiro S. Hata, hosted by Peter Lawson, Managing Director and Equity Research Analyst
- 2025 RBC Capital Markets Global Healthcare Conference on May 20th, 2025 at 8:30 AM ET - including a fireside chat with CEO Hata, hosted by Gregory Renza, Director and Senior Biotechnology Research Analyst
Live audio webcasts will be available on the IDEAYA website's Investors/Events section, with recordings accessible for 30 days after each event.
Positive
- None.
Negative
- None.
News Market Reaction – IDYA
On the day this news was published, IDYA gained 3.95%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Barclays Hosted: Peter Lawson's Catalyst & Key Debate Calls & Investor 1x1's
Thursday, May 8th, 2025 at 11:00 AM ET
- Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Peter Lawson, D.Phil., Managing Director, Equity Research Analyst
2025 RBC Capital Markets Global Healthcare Conference
Tuesday, May 20th, 2025 at 8:30 AM ET
- Fireside chat with Yujiro S. Hata, President and Chief Executive Officer hosted by Gregory Renza, M.D., Director and Senior Biotechnology Research Analyst
A live audio webcast of the conference events, as permitted by the conference host, will be available under the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of the webcasts will be accessible for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Chief Accounting Officer
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-upcoming-may-2025-investor-relations-events-302438987.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
What investor events will IDEAYA Biosciences (IDYA) attend in May 2025?
How can investors access IDEAYA Biosciences' (IDYA) May 2025 conference presentations?
Who will represent IDEAYA Biosciences (IDYA) at the May 2025 investor conferences?
What time is IDEAYA Biosciences' (IDYA) presentation at the 2025 RBC Capital Markets Healthcare Conference?
